Publications by authors named "Isha Mol"

Claim this Profile
E
Elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison.
Isha Mol, Yannan Hu, Thomas W LeBlanc, Joseph C Cappelleri, Haitao Chu

J Comp Eff Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-Adjusted Indirect Comparison of Elranatamab versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma: Updated Results.
Isha Mol, Yannan Hu, Thomas W LeBlanc, Joseph C Cappelleri, Haitao Chu

J Blood Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
Bhavesh Shah, Rickard Sandin, Yun Liu, Laura R Bobolts, Yannan Hu, Isha Mol

Clinicoecon Outcomes Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma.
Isha Mol, Yannan Hu, Thomas W LeBlanc, Joseph C Cappelleri, Haitao Chu

Leuk Lymphoma· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma.
Isha Mol, Yannan Hu, Thomas W LeBlanc, Joseph C Cappelleri, Haitao Chu

Curr Med Res Opin· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis